Last reviewed · How we verify

superficial punctate keratitis — Treatment Landscape & Competitive Intelligence

superficial punctate keratitis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating superficial punctate keratitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Loteprednol Etabonate LOTEPREDNOL Bausch And Lomb 2020-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bausch And Lomb · 1 drug in superficial punctate keratitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in superficial punctate keratitis:

Cite this brief

Drug Landscape (2026). superficial punctate keratitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/superficial-punctate-keratitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing